Health
Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines – News-Medical.Net
A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against…
A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv* preprint server.
SARS-Cov-2, the pathogen and causative agent of coronavirus disease 19 (COVID-19), has been responsible for more than 1.2…
-
General18 hours agoIran’s currency at record low as tensions run high
-
Noosa News24 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
Noosa News23 hours agoHundreds pack neighbourhood for no-reserve auction of ready-made charity home
-
General11 hours agoTexas opens probe into Kellogg’s health claims, dyes